BFA
LCTX icon

BlackRock Fund Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History

BlackRock Fund Advisors’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$8.11M Buy
2,568,374
+338,900
+15% +$1.04M ﹤0.01% 2690
2016
Q3 		$7.61M Buy
2,229,474
+314,517
+16% +$869K ﹤0.01% 2625
2016
Q2 		$4.37M Buy
1,914,957
+238,445
+14% +$585K ﹤0.01% 2870
2016
Q1 		$4.21M Sell
1,676,512
-219,749
-12% -$490K ﹤0.01% 2830
2015
Q4 		$6.28M Buy
1,896,261
+169,190
+10% +$506K ﹤0.01% 2710
2015
Q3 		$4.18M Sell
1,727,071
-17,167
-1% -$44.4K ﹤0.01% 2893
2015
Q2 		$5.11M Sell
1,744,238
-48,685
-3% -$189K ﹤0.01% 2911
2015
Q1 		$7.19M Buy
1,792,923
+34,391
+2% +$119K ﹤0.01% 2628
2014
Q4 		$5.29M Buy
1,758,532
+264,468
+18% +$715K ﹤0.01% 2845
2014
Q3 		$3.79M Sell
1,494,064
-58,694
-4% -$141K ﹤0.01% 2901
2014
Q2 		$3.82M Buy
1,552,758
+246,132
+19% +$556K ﹤0.01% 2981
2014
Q1 		$3.47M Buy
1,306,626
+69,226
+6% +$204K ﹤0.01% 3009
2013
Q4 		$3.6M Sell
1,237,400
-55,165
-4% -$167K ﹤0.01% 2998
2013
Q3 		$3.96M Buy
1,292,565
+149,915
+13% +$474K ﹤0.01% 2950
2013
Q2 		$3.65M Buy
+1,142,650
New +$3.66M ﹤0.01% 2897

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $302M AUM 117.41% 1-Year Est. Return
DWM
Destination Wealth Management Walnut Creek, California $4.28B AUM 19.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

BlackRock Fund Advisors's LCTX Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Lineage Cell Therapeutics (LCTX) stake by 15% in Q4 2016, buying an estimated $1.04M and bringing the position to 2,568,374 shares worth $8.11M. The position accounts for ﹤0.01% of the portfolio, ranked #2690.

BlackRock Fund Advisors first reported a position in LCTX in Q2 2013 and has held it in 15 quarters since. 92 funds tracked by Wall St. Rank hold LCTX as of Q4 2016.

  • BlackRock Fund Advisors held 2,568,374 shares of Lineage Cell Therapeutics worth $8.11M as of Q4 2016.
  • BlackRock Fund Advisors bought 338,900 Lineage Cell Therapeutics shares in Q4 2016, an estimated $1.04M.
  • Lineage Cell Therapeutics made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #2690 holding.
  • BlackRock Fund Advisors first reported a position in Lineage Cell Therapeutics in Q2 2013 and has held it in 15 quarters since.
  • 92 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.